☆ 4.7 Article

Exacerbation of Cerebral Radiation Necrosis by Bevacizumab

JOURNAL OF CLINICAL ONCOLOGY (2011)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 29, 期 7, 页码 E159-E162

出版社

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2010.31.4815

关键词

-

类别

Oncology

资金

Genentech

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Temporal Lobe Necrosis Following Radiotherapy in Nasopharyngeal Carcinoma: New Insight Into the Management

Xin Zhou, Peiyao Liu, Xiaoshen Wang

Summary: Cerebral radiation necrosis (CRN) is a common and severe sequelae following radiation therapy for nasopharyngeal carcinoma, but advancements in technology and the use of IMRT and new medications have shown promise in reversing radiation-induced necrosis.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Utility of Amino Acid PET in the Differential Diagnosis of Recurrent Brain Metastases and Treatment-Related Changes: A Meta-analysis

Timo Schluermann, Birgit Waschulzik, Stephanie Combs, Jens Gempt, Benedikt Wiestler, Wolfgang Weber, Igor Yakushev

Summary: This study aimed to summarize the diagnostic utility of amino acid PET in recurrent brain metastases. The analysis of 12 studies with a total of 547 lesions in 397 patients showed that amino acid PET had good accuracy in the differential diagnosis of recurrent brain metastases, with a specificity of 84%, suggesting it can reduce the need for invasive procedures and overtreatment.

JOURNAL OF NUCLEAR MEDICINE (2023)

添加到收藏夹

Review Oncology

Bevacizumab vs laser interstitial thermal therapy in cerebral radiation necrosis from brain metastases: a systematic review and meta-analysis

Paolo Palmisciano, Ali S. Haider, Chibueze D. Nwagwu, Waseem Wahood, Salah G. Aoun, Kalil G. Abdullah, Tarek Y. El Ahmadieh

Summary: Bevacizumab and LITT are both safe and effective treatments for RN from brain metastases. Clinical and radiological outcomes are comparable, but LITT may offer superior survival benefits in certain patients. Further studies are needed to determine the optimal treatment for individual patients.

JOURNAL OF NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Single-shot bevacizumab for cerebral radiation injury

Martin Voss, Katharina J. Wenger, Emmanouil Fokas, Marie-Therese Forster, Joachim P. Steinbach, Michael W. Ronellenfitsch

Summary: Single-shot bevacizumab shows significant efficacy in treating cerebral radiation injury by reducing edema and decreasing the need for steroids. However, long-lasting control is rare, with a median time to treatment failure of 3 months. In cases where a full protocol of four infusions is not feasible, single-shot bevacizumab treatment may be considered.

BMC NEUROLOGY (2021)

添加到收藏夹

Review Oncology

Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review

Guixiang Liao, Muhammad Khan, Zhihong Zhao, Sumbal Arooj, Maosheng Yan, Xianming Li

Summary: A systematic review of studies on the efficacy and safety of bevacizumab in patients with RBN showed promising results in terms of radiographic and clinical improvements. Bevacizumab was found to be more effective than corticosteroid-based treatments, with comparable safety profiles.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis

Muhammad Khan, Zhihong Zhao, Sumbal Arooj, Guixiang Liao

Summary: Bevacizumab shows promise as a treatment strategy for patients with radiation necrosis and brain metastatic disease, with radiographic response and clinical improvement observed without serious adverse events. Further high-quality evidence is needed to establish a recommendation for bevacizumab in this patient population.

BMC CANCER (2021)

添加到收藏夹

Article Surgery

Low-Dosage Bevacizumab Treatment: Effect on Radiation Necrosis After Gamma Knife Radiosurgery for Brain Metastases

Yuxiang Weng, Jie Shen, Luyuan Zhang, Zebin Fang, Feng Xiao, Chao Zhang, Zuoxu Fan, Kaiyuan Huang, Liyun Wang, Bin Huang, Fan Wu, Tiesong Zhang, Qingsheng Xu

Summary: The study showed that low-dose bevacizumab is effective in treating cerebral radiation necrosis after Gamma Knife radiosurgery for brain metastases. Patients experienced improvements in symptoms and neurological function, with no observed side effects.

FRONTIERS IN SURGERY (2021)

添加到收藏夹

Article Oncology

Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series

Jens Tijtgat, Evan Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, Anne Marie Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, Bart Neyns

Summary: Focal radiation necrosis of the brain (fRNB) is a potential adverse event following stereotactic radiation therapy (SRT) or stereotactic radiosurgery (SRS), with higher incidence in cancer patients treated with immune checkpoint inhibitors. A low-dose regimen of bevacizumab (BEV) was found to be effective in improving clinical symptoms and reducing edema volume in fRNB patients, without significant adverse effects. This fixed low-dose BEV regimen may serve as a well-tolerated and cost-effective alternative treatment option for fRNB, warranting further investigation.

CANCERS (2023)

添加到收藏夹

Article Oncology

Iatrogenic influence on prognosis of radiation-induced contrast enhancements in patients with glioma WHO 1-3 following photon and proton radiotherapy

Tanja Eichkorn, Jonathan W. Lischalk, Elisabetta Sandrini, Eva Meixner, Sebastian Regnery, Thomas Held, Julia Bauer, Emanuel Bahn, Semi Harrabi, Juliane Hoerner-Rieber, Klaus Herfarth, Juergen Debus, Laila Koenig

Summary: Radiation-induced contrast enhancements (RICE) are a common side effect following radiotherapy for gliomas, and correct diagnosis and treatment decisions for RICE are challenging. Research shows that different treatments result in varying outcomes for RICE, emphasizing the importance of making the right treatment decisions.

RADIOTHERAPY AND ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Bevacizumab Combined with Corticosteroids Does Not Improve the Clinical Outcome of Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis

Honghong Li, Xiaoming Rong, Weihan Hu, Yuhua Yang, Ming Lei, Wenjie Wen, Zongwei Yue, Xiaolong Huang, Melvin L. K. Chua, Yi Li, Jinhua Cai, Lei He, Dong Pan, Jinping Cheng, Yaxuan Pi, Ruiqi Xue, Yongteng Xu, Yamei Tang

Summary: The study compared the clinical outcomes of patients with radiation-induced brain necrosis who were treated with bevacizumab combined with corticosteroids and those with bevacizumab monotherapy, showing that the combination therapy did not lead to better clinical outcomes and did not reduce recurrence rates. The most common adverse events of bevacizumab were hypertension, nosebleed, and fatigue, with no significant difference in severe adverse events between the two groups.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

An Analysis of Risk Factors for Radiation Necrosis Following Cranial Radiation

Caleb Nissen, Jun Ying, Madison Newkirk, Ganesh Narayanasamy, Gary Lewis, Fen Xia

Summary: This study aimed to identify risk factors for cerebral radiation necrosis. The candidate risk factors included radiation adjuvant to surgery, concurrent systemic therapy, total dose, and V12. The study found a positive correlation between concurrent systemic therapy and adjuvant RT with the incidence of radiation necrosis. Greater total RT dose and V12 were also associated with the risk of developing radiation necrosis following brain RT.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

添加到收藏夹

Article Oncology

Blood-Brain Barrier Repair of Bevacizumab and Corticosteroid as Prediction of Clinical Improvement and Relapse Risk in Radiation-Induced Brain Necrosis: A Retrospective Observational Study

Ruiqi Xue, Meiwei Chen, Jinhua Cai, Zhenhong Deng, Dong Pan, Xiaohuan Liu, Yi Li, Xiaoming Rong, Honghong Li, Yongteng Xu, Qingyu Shen, Yamei Tang

Summary: The study found that bevacizumab improved blood-brain barrier leakage in radiation-induced brain necrosis. DCE parameters may be useful in predicting treatment response and relapse after using bevacizumab.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism

Friederike Hesse, Alan J. Wright, Vencel Somai, Flaviu Bulat, Felix Kreis, Kevin M. Brindle

Summary: The study demonstrates that detecting fumarate metabolism using H-2 MRI can early identify tumor cell death in glioblastoma following chemoradiation, potentially improving the clinical evaluation of treatment response.

CANCER RESEARCH (2022)

添加到收藏夹

Article Clinical Neurology

Single low-dose targeted bevacizumab infusion in adult patients with steroid-refractory radiation necrosis of the brain: a phase II open-label prospective clinical trial

Shervin R. Dashti, Robert J. Kadner, Bradley S. Folley, Jason P. Sheehan, Dong Y. Han, Richard J. Kryscio, Mary B. Carter, Lisa B. E. Shields, Brian M. Plato, Renato La Rocca, Aaron C. Spalding, Tom L. Yao, Justin F. Fraser

Summary: This study aimed to evaluate the safety and efficacy of a single low-dose targeted bevacizumab infusion in patients with steroid-refractory brain radiation necrosis (RN). The results showed that after 12 months of treatment, 80% of patients had a > 25% decrease in RN and vasogenic edema volume.

JOURNAL OF NEUROSURGERY (2022)

添加到收藏夹

Article Oncology

Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001)

Woo Yeon Hwang, Suk-Joon Chang, Hee Seung Kim, Nam Kyeong Kim, Tae Hun Kim, Yeorae Kim, Tae Wook Kong, Eun Ji Lee, Soo Jin Park, Seung Hyuk Shim, Joo-Hyuk Son, Dong Hoon Suh, Eun Jung Yang

Summary: This study aims to evaluate the incidence and risk factors for gastrointestinal and genitourinary fistula or perforation in recurrent cervical cancer patients who received pelvic radiation therapy. The study found that the inclusion of bevacizumab in chemotherapy regimens increases the risk of fistula/perforation formation. No other independent risk factors were identified.

BMC CANCER (2022)

添加到收藏夹

Article Clinical Neurology

Epigenomic, genomic, and transcriptomic landscape of schwannomatosis

Sheila Mansouri, Suganth Suppiah, Yasin Mamatjan, Irene Paganini, Jeffrey C. Liu, Shirin Karimi, Vikas Patil, Farshad Nassiri, Olivia Singh, Yogi Sundaravadanam, Prisni Rath, Roberta Sestini, Francesca Gensini, Sameer Agnihotri, Jaishri Blakeley, Kimberly Ostrow, David Largaespada, Scott R. Plotkin, Anat Stemmer-Rachamimov, Marcela Maria Ferrer, Trevor J. Pugh, Kenneth D. Aldape, Laura Papi, Gelareh Zadeh

Summary: Schwannomatosis is a genetic cancer predisposition syndrome characterized by multiple neuronal tumors called schwannomas. Genomic analysis revealed distinct features in SWNTS-SWNs compared to non-syndromic sporadic SWNs, including four DNA methylation subgroups and novel genetic alterations. Specific transcriptional programs associated with painful SWNTS-SWNs were identified, which may be utilized for syndrome management.

ACTA NEUROPATHOLOGICA (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial

Michael J. Fisher, Chie-Schin Shih, Steven D. Rhodes, Amy E. Armstrong, Pamela L. Wolters, Eva Dombi, Chi Zhang, Steven P. Angus, Gary L. Johnson, Roger J. Packer, Jeffrey C. Allen, Nicole J. Ullrich, Stewart Goldman, David H. Gutmann, Scott R. Plotkin, Tena Rosser, Kent A. Robertson, Brigitte C. Widemann, Abbi E. Smith, Waylan K. Bessler, Yongzheng He, Su-Jung Park, Julie A. Mund, Li Jiang, Khadijeh Bijangi-Vishehsaraei, Coretta Thomas Robinson, Gary R. Cutter, Bruce R. Korf, Jaishri O. Blakeley, D. Wade Clapp

Summary: Cabozantinib, an inhibitor of multiple receptor tyrosine kinases, has shown efficacy in reducing plexiform neurofibroma volume and improving pain in patients with NF1, meeting the primary outcome of the phase II trial. However, some patients experienced adverse events leading to dose reduction or discontinuation of therapy.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

Brian D. Weiss, Pamela L. Wolters, Scott R. Plotkin, Brigitte C. Widemann, James H. Tonsgard, Jaishri Blakeley, Jeffrey C. Allen, Elizabeth Schorry, Bruce Korf, Nathan J. Robison, Stewart Goldman, Alexander A. Vinks, Chie Emoto, Tsuyoshi Fukuda, Coretta T. Robinson, Gary Cutter, Lloyd Edwards, Eva Dombi, Nancy Ratner, Roger Packer, Michael J. Fisher

Summary: This study conducted a phase II trial of mirdametinib in NF1 patients with PNs, revealing a 42% partial response rate and preliminary evidence of reduced pain in some patients. It represents the first characterization of mirdametinib activity and pharmacokinetics in this patient population and is the first published response study for MAPK/ERK kinase inhibitors in adults with NF1 and PNs.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Letter Genetics & Heredity

The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research

Heather B. Radtke, Bonita P. Klein-Tasman, Vanessa L. Merker, Pamela Knight, Nicole J. Ullrich, Justin T. Jordan, Bruce Korf, Scott R. Plotkin

Summary: The COVID-19 pandemic has significantly impacted NF care and research, with changes in clinician roles, decreased patient volumes, and widespread adoption of telehealth. Providers report high satisfaction with telehealth but express concerns about the inability to conduct physical examinations.

ORPHANET JOURNAL OF RARE DISEASES (2021)

添加到收藏夹

Article Oncology

Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma

Matthias A. Karajannis, Audrey Mauguen, Ekrem Maloku, Qingwen Xu, Erin M. Dunbar, Scott R. Plotkin, Anna Yaffee, Shiyang Wang, J. Thomas Roland, Chandranath Sen, Dimitris G. Placantonakis, John G. Golfinos, Jeffrey C. Allen, Nicholas A. Vitanza, Luis A. Chiriboga, Robert J. Schneider, Jingjing Deng, Thomas A. Neubert, Judith D. Goldberg, David Zagzag, Filippo G. Giancotti, Jaishri O. Blakeley

Summary: Inhibition of mTORC1 signaling with everolimus showed limited antitumor effect in patients with NF2, potentially due to incomplete inhibition of mTORC1 and downstream signaling. These findings provide insights for the design of future studies targeting mTORC1 in meningiomas and schwannomas.

MOLECULAR CANCER THERAPEUTICS (2021)

添加到收藏夹

Article Oncology

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Andrew B. Lassman, Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek M. E. Walenkamp, Adam L. Green, Kai Li, Christopher J. Walker, Hua Chang, Sharon Tamir, Leah Henegar, Yao Shen, Mariano J. Alvarez, Andrea Califano, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, Morten Mau-Sorensen

Summary: In patients with glioblastoma, single-agent Selinxor therapy achieved intratumoral penetration and demonstrated some efficacy with manageable side effects. Importantly, the dosage of Selinxor needs to be adjusted based on patient tolerability.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Genetics & Heredity

Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis

Rebecca Burns, Kristin Niendorf, Kathleen Steinberg, Amy Mueller, Ina Ly, Justin T. Jordan, Scott R. Plotkin, Stephanie R. Hicks

Summary: This study compared the efficacy of germline-only versus paired genetic testing in clarifying the diagnosis of patients with features of NF2 and SWN. The results showed that paired testing had a higher likelihood of providing diagnostic clarity, especially for patients who had analysis of multiple tumors.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2022)

添加到收藏夹

Article Hematology

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Matthew J. Frigault, Jorg Dietrich, Kathleen Gallagher, Mark Roschewski, Justin T. Jordan, Deborah Forst, Scott R. Plotkin, Daniella Cook, Keagan S. Casey, Kevin A. Lindell, Gabriel D. Depinho, Katelin Katsis, Eva Lynn Elder, Mark B. Leick, Bryan Choi, Nora Horick, Frederic Preffer, Meredith Saylor, Steven McAfee, Paul O'Donnell, Thomas R. Spitzer, Bimalangshu Dey, Zachariah DeFilipp, Areej El-Jawahri, Tracy T. Batchelor, Marcela Maus, Yi-Bin Chen

Summary: This study conducted a clinical trial of tisagenlecleucel in highly refractory patients with primary central nervous system lymphoma (PCNSL). The results showed that most patients responded well to the treatment and there were no severe side effects. This suggests that tisagenlecleucel is safe and effective in this patient population.

BLOOD (2022)

添加到收藏夹

Article Genetics & Heredity

Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis

Vanessa L. Merker, Bronwyn Slobogean, Justin T. Jordan, Shannon Langmead, Mark Meterko, Martin P. Charns, A. Rani Elwy, Jaishri O. Blakeley, Scott R. Plotkin

Summary: This study evaluated the extent and reasons for diagnostic delays and errors in schwannomatosis, a neurogenetic syndrome characterized by nerve sheath tumors and chronic pain. The results showed a long median time to diagnosis and a high misdiagnosis rate in patients with schwannomatosis. The study suggests that interventions in clinician education, genetic testing availability, expert review of pathology findings, and automatic triggers for genetics referrals may improve the diagnosis of schwannomatosis.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2022)

添加到收藏夹

Article Genetics & Heredity

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

Scott R. Plotkin, Ludwine Messiaen, Eric Legius, Patrice Pancza, Robert A. Avery, Jaishri O. Blakeley, Dusica Babovic-Vuksanovic, Rosalie Ferner, Michael J. Fisher, Jan M. Friedman, Marco Giovannini, David H. Gutmann, Clemens Oliver Hanemann, Michel Kalamarides, Hildegard Kehrer-Sawatzki, Bruce R. Korf, Victor-Felix Mautner, Mia MacCollin, Laura Papi, Katherine A. Rauen, Vincent Riccardi, Elizabeth Schorry, Miriam J. Smith, Anat Stemmer-Rachamimov, David A. Stevenson, Nicole J. Ullrich, David Viskochil, Katharina Wimmer, Kaleb Yohay, Susan M. Huson, Pierre Wolkenstein, D. Gareth Evans

Summary: The study aims to update the diagnostic criteria for neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) by incorporating recent advances in genetics, ophthalmology, neuropathology, and neuroimaging. The updated criteria include clinical features and genetic testing, emphasizing the phenotypic overlap between the two conditions.

GENETICS IN MEDICINE (2022)

添加到收藏夹

Article Oncology

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma

Scott R. Plotkin, Jeffrey Allen, Girish Dhall, Jian L. Campian, D. Wade Clapp, Michael J. Fisher, Rakesh K. Jain, James Tonsgard, Nicole J. Ullrich, Coretta Thomas, Lloyd J. Edwards, Bruce Korf, Roger Packer, Matthias A. Karajannis, Jaishri O. Blakeley

Summary: In this prospective multicenter phase II study, the efficacy, safety, and tolerability of bevacizumab for maintenance therapy in persons with NF2-SWN and hearing loss due to VS were evaluated. The results showed that maintenance bevacizumab (5 mg/kg every 3 weeks) was associated with high rates of hearing and tumor stability during 18 months of follow-up. No new unexpected adverse events related to bevacizumab were identified in this population.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Genetics & Heredity

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis

Jineta Banerjee, Jan M. Friedman, Laura J. Klesse, Kaleb H. Yohay, Justin T. Jordan, Scott R. Plotkin, Robert J. Allaway, Jaishri O. Blakeley

Summary: This study investigated whether patients with rare diseases such as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), or schwannomatosis (SWN) are more susceptible to SARS-CoV-2 infection and severe COVID-19. The results showed that the proportion of positive cases in NF1, NF2, or SWN patients was not significantly higher than in individuals without these rare diseases. There were no severe outcomes reported in the NF2 or SWN cohorts, and the proportion of severe outcomes in NF1 patients was similar to other rare disease cohorts and the general population.

GENETICS IN MEDICINE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

Roberta L. Beauchamp, Serkan Erdin, Luke Witt, Justin T. Jordan, Scott R. Plotkin, James F. Gusella, Vijaya Ramesh

Summary: Loss of NF2 leads to activation of NRG1-ERBB3 signaling, which may involve potential autocrine signaling. Inhibition of mTORC1/2 decreases NRG1-ERBB3 expression while upregulating pAkt T308 through an adaptive response involving IGF1R/insulin receptor. Co-targeting mTORC1/2 and IGF1R/insulin receptor pathways shows synergistic effects on viability in NF2-deficient MN.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

添加到收藏夹

Article Clinical Neurology

Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1

Sheilagh Maguiness, Yemima Berman, Nathan Rubin, Melissa Dodds, Scott R. Plotkin, Claire Wong, Christopher Moertel

Summary: In patients with NF1, female sex, number of facial neurofibromas, and total neurofibromas are highly correlated with Skindex scores, and the site at UMN had lower average scores but these differences were almost entirely removed after adjusting for other factors.

NEUROLOGY (2021)

添加到收藏夹

Correction Clinical Neurology

Epigenomic, genomic, and transcriptomic landscape of schwannomatosis (October, 10.1007/s00401-020-02230-x, 2020)

Sheila Mansouri, Suganth Suppiah, Yasin Mamatjan, Irene Paganini, Jeffrey C. Liu, Shirin Karimi, Vikas Patil, Farshad Nassiri, Olivia Singh, Yogi Sundaravadanam, Prisni Rath, Roberta Sestini, Francesca Gensini, Sameer Agnihotri, Jaishri Blakeley, Kimberly Ostrow, David Largaespada, Scott R. Plotkin, Anat Stemmer-Rachamimov, Marcela Maria Ferrer, Trevor J. Pugh, Kenneth D. Aldape, Laura Papi, Gelareh Zadeh

Summary: The original publication failed to include corresponding author information, specifically neglecting to mention Dr. Zadeh.

ACTA NEUROPATHOLOGICA (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.